A Look at FDA Approvals for the Treatment of Lung Cancer in 2020
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer...
Category: Policy
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer...
Breast cancer is the most common cancer among women in the United States and worldwide, with an estimated 2.1 million women diagnosed each year....
Guest post by Jennifer J. Gao, Patricia Keegan, Paul G. Kluetz, and Richard Pazdur Editor’s note: The authors all...
On April 27, cancer researchers, health care professionals, patients, advocates, and policymakers around the world logged on to their...
By Carmine S. Leggett, PhD Clinical trials in oncology have changed the face of cancer treatment, allowing cancer researchers...
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
The first new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) in 2020 are for the...
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
In the final days of 2019, the U.S. Food and Drug Administration (FDA) expanded the use of a previously...
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and...